In an animal model of multiple sclerosis, treatment with fluvoxamine was shown to decrease disease severity by decreasing serum levels of the pro-inflammatory cytokine IFN-γ and reducing demyelination, suggesting its potential as a therapeutic agent in multiple sclerosis (MS) [128]. This evidence concerns the gene IFNG and multiple sclerosis.